Soleno Therapeutics (SLNO) Long-Term Investments (2024 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Long-Term Investments of $273.4 million for Q1 2026, up 36.27% quarter-over-quarter from $200.6 million in Q4 2025.
Soleno Therapeutics (SLNO) Long-Term Investments (2024 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Long-Term Investments for 3 consecutive years, with $273.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments changed N/A year-over-year to $273.4 million; the TTM figure through Mar 2026 stood at $273.4 million (changed N/A YoY), while the FY2025 annual figure was $200.6 million, up 637.26% from the prior year.
- Long-Term Investments grew to $273.4 million in Q1 2026 per SLNO's latest filing, from $200.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $273.4 million in Q1 2026 and bottomed at $7.0 million in Q2 2025.
- Historically, Long-Term Investments has averaged $78.8 million across 3 years, with a median of $28.2 million in 2024.
- On a YoY basis, Long-Term Investments climbed as much as 637.26% in 2025 and fell as far as 75.43% in 2025.
- Soleno Therapeutics' Long-Term Investments stood at $27.2 million in 2024, then jumped by 637.26% to $200.6 million in 2025, then soared by 36.27% to $273.4 million in 2026.
- Business Quant data shows SLNO's Long-Term Investments at $273.4 million in Q1 2026, $200.6 million in Q4 2025, and $57.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 273.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 273.38 Mn |
| Dec 31, 2025 | 200.62 Mn |
| Sep 30, 2025 | 57.15 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Dec 31, 2024 | 27.21 Mn |
| Sep 30, 2024 | 27.90 Mn |
| Jun 30, 2024 | 28.50 Mn |
| Mar 31, 2024 | 8.80 Mn |